Drug Profile
Fipravirimat - ViiV Healthcare
Alternative Names: 3640254; BMS 986197; GSK-254; GSK-3640254Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer GSK; ViiV Healthcare
- Class Antiretrovirals
- Mechanism of Action Capsid protein inhibitors; HIV integrase inhibitors; HIV replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 08 Sep 2023 ViiV Healthcare terminates the phase IIb DYNAMIC trial for HIV infections (Combination therapy, Treatment-naïve) in US, Argentina, Canada, France, Germany, Italy, Portugal, Puerto Rico, South Africa and Spain (PO), due to company strategy for portfolio progression (NCT04900038)
- 29 May 2023 ViiV Healthcare terminates phase II trials in HIV infections (Combination therapy, Treatment-naive) in Switzerland, Spain, Russia, South Africa, Italy, Germany, Canada, Argentina, USA (PO) (NCT04493216)
- 02 May 2023 Discontinued - Phase-I for HIV infections (Combination therapy, In volunteers) in USA (PO) (GSK pipeline, April 2023)